spacer
home > ict > autumn 2018 > quality upkeep
PUBLICATIONS
International Clinical Trials

Quality Upkeep

To ensure a smooth transition from the pre-authorisation to the post-authorisation phase of the lifecycle of a medicinal product, the marketing authorisation (MA) applicant is responsible for ensuring a robust pharmacovigilance (PV) system is in place to monitor patient safety once the product is on the market. During clinical trials, patient exposure is limited and closely monitored, and very specific criteria must be met for patients who are eligible to take part in the study. However, once the product is on the market and more widely available, patient exposure will be much more widespread and patients may experience adverse reactions (ARs) that have not been observed previously in a clinical trial setting.

To maintain compliance with EU post-marketing regulatory requirements, the MA holder (MAH) must ensure that the following are in place:

• PV systems (including appropriate technology, quality management system, and PV processes)
• Qualified Person for PV (QPPV) and deputy and local safety-responsible representatives (where required under national legislation)
• PV system master file (PSMF)
• Risk management and minimisation systems
• Signal management • Global literature search strategy
• EudraVigilance (EV) maintenance, including Article 57 database

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
David Hukin is the Head of Pharmacovigilance and the PV team at Quanticate. David has a PhD in cell physiology and biophysics and 15 years’ experience in the pharmaceutical industry, with more than 14 years working in the PV sector. He has worked across speciality pharma/biotechnology companies and has gained preand post-marketing experience in a range of therapeutic areas, including gastroenterology, hepatology, neurology, oncology, psychiatric conditions, ATMPs, and orphan drug indication products for rare diseases. Since 2015, David has worked in the specialist PV service provider sector, leading multiple large teams responsible for clinical and post-marketing for customers ranging from small pharma/ biotech to large speciality and generic companies, before joining Quanticate in 2018.
spacer
David Hukin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology

PHILADELPHIA – August 12, 2019: Signant Health (signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. By becoming a Signant Partner, CROs will benefit from new commercial and operational advantages that only come with membership.
More info >>

White Papers
 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement